Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Emergent BioSolutions Inc Reaffirms FY 2013; Issues Q1 2013 Revenue Guidance Below Analysts' Estimates


Thursday, 7 Mar 2013 04:01pm EST 

Emergent BioSolutions Inc reaffirmed it fiscal 2013 guidance and expects total revenue of $290 to $310 million. For first quarter of 2013, it expects total revenues of $40 to $50 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $301 million for fiscal 2013; revenue of $60 million for first quarter of 2013. 

Company Quote

21.6
 --
23 Oct 2014